Non-Hodgkin Lymphoma (Lymphosarcoma)

8782  relevant articles (766 outcomes, 1330 trials/studies) found for this Disease

Lymphosarcoma; Non-Hodgkin's Lymphoma; Lymphoma, Small Cleaved Cell, Diffuse; Lymphoma, High Grade; Lymphoma, Intermediate Grade; Lymphoma, Low Grade; Lymphoma, Small Noncleaved Cell; Non-Hodgkins Lymphoma; Lymphoma, Mixed Cell, Diffuse; Lymphoma, Mixed Cell; Lymphoma, Non Hodgkin; Lymphoma, Non-Hodgkin's; Small Non-Cleaved-Cell Lymphoma; Lymphoma, Non-Hodgkin; Diffuse Mixed Small and Large Cell Lymphoma; Diffuse Mixed-Cell Lymphoma; Diffuse Small Cleaved-Cell Lymphoma; Diffuse Undifferentiated Lymphoma; Lymphatic Sarcoma; Lymphoma, Atypical Diffuse Small Lymphoid; Lymphoma, Diffuse; Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic; Lymphoma, High-Grade; Lymphoma, Intermediate-Grade; Lymphoma, Low-Grade; Lymphoma, Mixed; Lymphoma, Mixed Lymphocytic-Histiocytic; Lymphoma, Mixed Small and Large Cell, Diffuse; Lymphoma, Mixed-Cell; Lymphoma, Mixed-Cell, Diffuse; Lymphoma, Non-Hodgkins; Lymphoma, Nonhodgkin's; Lymphoma, Nonhodgkins; Lymphoma, Pleomorphic; Lymphoma, Small Cleaved-Cell, Diffuse; Lymphoma, Small Non-Cleaved-Cell; Lymphoma, Small Noncleaved-Cell; Lymphoma, Small and Large Cleaved-Cell, Diffuse; Lymphoma, Undifferentiated; Lymphoma, Undifferentiated, Diffuse; Mixed Small and Large Cell Lymphoma, Diffuse; Mixed-Cell Lymphoma; Mixed-Cell Lymphoma, Diffuse; Reticulosarcoma; Reticulum-Cell Sarcoma; Sarcoma, Lymphatic; Sarcoma, Reticulum-Cell; Small Cleaved-Cell Lymphoma, Diffuse; Small Noncleaved-Cell Lymphoma; Undifferentiated Lymphoma; Diffuse Lymphoma; Diffuse Lymphomas; Diffuse Mixed Cell Lymphoma; Diffuse Mixed-Cell Lymphomas; Diffuse Small Cleaved Cell Lymphoma; Diffuse Undifferentiated Lymphomas; High-Grade Lymphoma; High-Grade Lymphomas; Intermediate-Grade Lymphoma; Intermediate-Grade Lymphomas; Low-Grade Lymphoma; Low-Grade Lymphomas; Lymphatic Sarcomas; Lymphocytic-Histiocytic Lymphoma, Mixed; Lymphocytic-Histiocytic Lymphomas, Mixed; Lymphoma, Diffuse Mixed-Cell; Lymphoma, Diffuse Undifferentiated; Lymphoma, Mixed Lymphocytic Histiocytic; Lymphoma, Non Hodgkin's; Lymphoma, Non Hodgkins; Lymphoma, Nonhodgkin; Lymphoma, Small Non Cleaved Cell; Lymphomas, Diffuse; Lymphomas, Diffuse Mixed-Cell; Lymphomas, Diffuse Undifferentiated; Lymphomas, High-Grade; Lymphomas, Intermediate-Grade; Lymphomas, Low-Grade; Lymphomas, Mixed; Lymphomas, Mixed Lymphocytic-Histiocytic; Lymphomas, Mixed-Cell; Lymphomas, Pleomorphic; Lymphomas, Small Non-Cleaved-Cell; Lymphomas, Small Noncleaved-Cell; Lymphomas, Undifferentiated; Lymphosarcomas; Mixed Cell Lymphoma; Mixed Cell Lymphoma, Diffuse; Mixed Lymphocytic-Histiocytic Lymphoma; Mixed Lymphocytic-Histiocytic Lymphomas; Mixed Lymphoma; Mixed Lymphomas; Mixed-Cell Lymphomas; Mixed-Cell Lymphomas, Diffuse; Non Hodgkin Lymphoma; Non Hodgkin's Lymphoma; Non-Cleaved-Cell Lymphoma, Small; Non-Cleaved-Cell Lymphomas, Small; Noncleaved-Cell Lymphoma, Small; Noncleaved-Cell Lymphomas, Small

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Hodgkin Disease (Hodgkin's Disease)
3.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
4.	Leukemia
5.	Lymphoma (Lymphomas)

Experts

1.	Witzig, Thomas E: 28 articles (06/2008 - 01/2002)
2.	Leonard, John P: 17 articles (06/2008 - 02/2002)
3.	Coiffier, Bertrand: 16 articles (11/2007 - 01/2002)
4.	Emmanouilides, Christos: 16 articles (11/2007 - 02/2002)
5.	Wiseman, Gregory A: 15 articles (10/2007 - 02/2002)
6.	Vose, Julie M: 14 articles (06/2008 - 01/2002)
7.	Goldenberg, David M: 13 articles (07/2008 - 01/2003)
8.	Czuczman, Myron S: 13 articles (12/2007 - 02/2002)
9.	Hartge, Patricia: 12 articles (08/2008 - 02/2005)
10.	Cerhan, James R: 12 articles (08/2008 - 11/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Non-Hodgkin Lymphoma:

1.	rituximab (Mabthera)FDA Link 04/01/2006 - "CHOP combined with rituximab (R-CHOP) is regarded as one of the most effective treatments for indolent B-cell non-Hodgkin lymphoma (B-NHL), however, its optimal combination schedule remains unknown. " 12/01/2004 - "The anti-CD20 antibody rituximab is useful in the treatment of certain B-cell malignancies, most notably non-Hodgkin's lymphoma. " 04/01/2004 - "Most experience is available for anti-CD20 (rituximab) which led to a significant improvement of the outcome in B-cell non-Hodgkin's lymphoma (NHL). " 02/01/2003 - "In summary, rituximab appears highly active as first-line single-agent therapy for indolent non-Hodgkin's lymphoma and responses may be improved with maintenance courses of rituximab. " 01/01/2003 - "Although the introduction of the monoclonal antibody rituximab 5 years ago led to a marked improvement in the treatment of non-Hodgkin's lymphoma (NHL), most patients do not experience a complete response to therapy, and many who do respond relapse. " Order ALL the reference details at left...
2.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/01/1991 - "A study has been in progress since June 1985 to evaluate the use of myeloablative therapy (cyclophosphamide [60 mg/kg x 2] and total body irradiation [200 cGy x 6]) followed by reinfusion of autologous bone marrow in patients in second or subsequent remission of B-cell non-Hodgkin's lymphoma. " 01/15/2004 - "CONCLUSIONS: Inadequate clearance of cyclophosphamide to active metabolites is associated with increased risk of recurrence of B-cell non-Hodgkin's lymphoma in children. " 01/15/2004 - "The median clearance of cyclophosphamide in patients who remain free of B-cell non-Hodgkin's lymphoma was 3.7 liter/h/m(2) (range, 2.3-5.0 liter/h/m(2)), compared with 2.2 (range, 1.5-2.5 liter/h/m(2)) in those with disease recurrence. " 01/01/1967 - "[Remission of the generalized radiologic pattern of reticulosarcoma of the skeletal system in the course of treatment with endoxan]" 10/01/1966 - "Efficacy of cyclophosphamide in the management of reticulum cell sarcoma." Order ALL the reference details at left...
3.	Doxorubicin (Adriamycin)FDA LinkGeneric 07/01/1999 - "CONCLUSIONS: The results suggest that doxorubicin cannot be recommended as a single agent for treatment of feline lymphosarcoma because of the rather poor remission rate achieved." 08/01/1986 - "Further studies investigating the efficacy of weekly versus conventional scheduling of doxorubicin are warranted in non-Hodgkin's lymphoma, particularly in light of published evidence that weekly doxorubicin administration is also less cardiotoxic than treatment given every 3 weeks." 06/01/2008 - "We evaluated the toxicity and efficacy of nonpegylated liposomal doxorubicin (Myocet) when substituted for conventional doxorubicin in the CHOP-21 regimen in the treatment of frail elderly patients with aggressive non-Hodgkin lymphoma. " 07/01/1999 - "OBJECTIVE: To determine the efficacy of doxorubicin when used alone in inducing remission in cats with lymphosarcoma. " 07/01/1999 - "Efficacy of doxorubicin as an induction agent for cats with lymphosarcoma." Order ALL the reference details at left...
4.	Vincristine (Oncovin)FDA LinkGeneric 06/15/1984 - "These data suggest the possibility of enhancing the therapeutic efficacy of vincristine in the treatment of non-Hodgkin's lymphoma by use of an infusion technique." 01/01/1990 - "Phase I and II trials of vincristine infusion have demonstrated the safety and efficacy of this approach in the treatment of patients with refractory non-Hodgkin's lymphoma. " 03/01/2004 - "A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma." 01/01/1989 - "Vincristine (VCR) given by infusion has been shown in a phase II trial to be active in some cases of non-Hodgkin's lymphoma despite prior exposure to bolus VCR. " 07/01/2008 - "Vincristine-induced fatal neuropathy in non-Hodgkin's lymphoma." Order ALL the reference details at left...
5.	Prednisone (Sone)FDA LinkGeneric 01/01/1959 - "[A case of reticulosarcoma treated with large doses of prednisone.]" 02/01/1957 - "[Reticulosarcoma of the scapula; treatment with delta cortisone.]" 09/01/2005 - "This therapy was modified from CHOP in the treatment of patients with non-Hodgkin's lymphoma: CTX 600 mg/m(2), VCR 1.1 mg/m(2) were administrated by intravenous infusion every 2-4 weeks, prednisone was given orally at 1 mg.kg(-1).d(-1) for seven days after each infusion. " 04/15/1998 - "The 8 patients with multicentric disease were further subdivided according to initial treatment: Three patients who received combination chemotherapy are currently alive and free of disease; 2 patients treated with prednisone are alive but have needed intermittent maintenance therapy for disease reactivations; and 2 patients treated with surgery only have died, 1 of infectious complications and 1 of non-Hodgkin lymphoma. " 08/01/1958 - "Cutaneous lymphoblastoma: a case of reticulum cell sarcoma with prominent skin manifestations and a brief but dramatic remission with prednisone therapy." Order ALL the reference details at left...
6.	Etoposide (VP 16)FDA LinkGeneric 09/07/1994 - "Aggressive non-Hodgkin's lymphoma in the elderly: an effective, well-tolerated treatment regimen containing extended-schedule etoposide." 06/01/1996 - "Promising results have been reported for patients with non-Hodgkin's lymphoma (NHL) receiving chronic oral etoposide. " 02/01/2000 - "This study was undertaken to investigate the pharmacokinetics of etoposide for optimizing its oral dosage in elderly patients with non-Hodgkin's lymphoma (NHL) using the fraction of dose absorbed calculated from the data generated from first oral and intravenous doses in the same patient. " 02/01/2000 - "Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient." 09/01/1998 - "[Total body irradiation etoposide followed by autologous hematopoietic stem cell transplantion for non-Hodgkin's lymphoma]" Order ALL the reference details at left...
7.	fludarabineIBA 09/01/2007 - "CONCLUSION: Fludarabine-containing regimens is well tolerated and effective in the treatment of low grade non-Hodgkin's lymphoma." 12/01/1999 - "Fludarabine is effective in chronic lymphocytic leukaemia (CLL) and low-grade non-Hodgkin's lymphoma (NHL). " 08/01/2002 - "Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma." 06/01/1996 - "The aim of the study was to investigate the therapeutic activity of Fludarabine in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) no longer responding to standard treatment. " 06/01/1996 - "Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma." Order ALL the reference details at left...
8.	Cytarabine (Cytosar-U)FDA LinkGeneric 01/01/1992 - "The results suggest that the cytarabine dose that is expected to be therapeutic for vitreoretinal non-Hodgkin's lymphoma (about 90 micrograms given in three doses of 30 micrograms) is non-toxic for ocular structures." 03/01/1987 - "Therefore, we began a phase II trial of the combination of HU and ara-C to determine the efficacy and toxicity of this combination in treatment of patients with refractory non-Hodgkin's lymphoma. " 09/01/1997 - "New regimens incorporating high-dose cytarabine for patients with poor prognosis, small noncleaved-cell lymphoma seem to improve survival. " 05/01/1994 - "PATIENTS AND METHODS: Twenty-six patients with relapsed (n = 16) or refractory (n = 10) non-Hodgkin's lymphoma were treated at our Centre by a modified E-SHAP regimen (cytosine arabinoside 1 gm/m2 one dose). " 11/15/1989 - "We conclude that high-dose ara-C given as 3g/m2 every 12 hours for four doses has a limited role when used as a single agent in the treatment of relapsed or refractory non-Hodgkin's lymphoma. " Order ALL the reference details at left...
9.	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/01/2004 - "In the treatment of advanced aggressive non-Hodgkin's lymphoma (NHL), we investigated the efficacy of granulocyte colony-stimulating factor (G-CSF)-supported, dose-intensified strategies. " 12/01/1995 - "Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen." 12/01/2009 - "In a phase 3 multicenter, randomized, double-blinded, placebo-controlled study of 298 patients with non-Hodgkin lymphoma (NHL), granulocyte colony-stimulating factor (G-CSF) plus plerixafor increased the proportion of patients who mobilized >or=5 x 10(6) CD34(+) hematopoietic stem cells (HSCs)/kg compared with placebo plus G-CSF (P < .001). " 12/01/2009 - "Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol." 04/01/2007 - "Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)." Order ALL the reference details at left...
10.	Mitoxantrone (Novantrone)FDA LinkGeneric 12/01/1987 - "The data indicate that mitoxantrone is effective in the treatment of non-Hodgkin's lymphoma with acceptable toxicity." 09/01/1993 - "In the trial (19 patients) the therapy was confined to patients with high and intermediate grade non-Hodgkin's lymphoma in which the combination was compared against single agent mitozantrone. " 01/01/1993 - "In order to evaluate the role of Mitoxantrone in the therapy of non-Hodgkin's lymphoma (NHL) (intermediate-high grade malignancy) a series of successive phase II-III studies were performed in a multicenter cooperative group. " 12/01/1990 - "Twenty-one consecutive previously untreated patients with low-grade non-Hodgkin's lymphoma were entered into a trial of mitoxantrone (5 mg/m2 daily for 3 days repeated every 3 weeks) between 1985 and 1986. " 04/01/2002 - "The role of mitoxantrone in non-Hodgkin's lymphoma." Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/2008 - "CONCLUSION: Gastric lymphosarcomas are sensitive to chemotherapy, thereby PCT only is effective in most patients. " 11/01/2001 - "BACKGROUND: A brief course of chemotherapy followed by radiation therapy was considered the best treatment for localized high-grade Non-Hodgkin's Lymphoma (NHL). " 11/01/1998 - "The use of intensive chemotherapy and incorporation of prophylactic treatment of the central nervous system have dramatically improved the outcome of children with non-Hodgkin's lymphoma (NHL). " 04/26/1990 - "We conclude that most children with localized non-Hodgkin's lymphoma can be cured by a chemotherapy regimen of reduced intensity and duration. " 05/01/2008 - "After inguinal orchyectomy the diagnosis for the first case was large and medium T cell diffuse lymphoma, stage I (E)-A; three years after chemotherapy (R-CHOP) the patient is in complete remission. " Order ALL the reference details at left...
2.	Combination Drug Therapy (Combination Chemotherapy) 03/01/2002 - "The use of effective combination chemotherapy for all stages and subtypes of non-Hodgkin"s lymphoma (NHL) in children has resulted in a striking improvement in cure rates. " 01/01/2002 - "MTX-based combination chemotherapy has yielded the best results to date but the prognosis of patients with PCNSL remains significantly worse than comparable patients with systemic non-Hodgkin's lymphoma (NHL). " 04/01/1975 - "In treating childhood lymphosarcoma, high-dose combination chemotherapy is most effective, when given as long-term therapy. " 10/01/1991 - "Treatment of low-grade lymphomas with combination chemotherapy results in complete remission rates varying from 25% to 70%. " 12/01/1985 - "[Patterns of relapse in non-Hodgkin's lymphoma after complete remission induced by combination chemotherapy]" Order ALL the reference details at left...
3.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 10/01/2002 - "To evaluate the effect on survival of negative immunomagnetic purging in aggressive B-cell non-Hodgkin's lymphoma (NHL), 20 patients retrospectively staged according to the age-adjusted International Prognostic Index as high-intermediate (11 patients) or high-risk (9 patients) received autologous bone marrow transplantation (ABMT) in first complete remission (CR1). " 10/01/2002 - "Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission." 09/01/1994 - "Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. " 08/01/1994 - "Conclusion: Autologous bone marrow transplantation is effective in patients with relapsed non-Hodgkin lymphoma and should be considered an important therapeutic option." 01/01/1994 - "One hundred and eighteen patients presenting with high-grade non-Hodgkin's lymphoma, undergoing autologous bone marrow transplantation (ABMT) in first complete remission (CR), have been reported to the European Group for Bone Marrow Transplantation (EBMT). " Order ALL the reference details at left...
4.	Stem Cell Transplantation 10/01/2002 - "Autologous stem cell transplantation as upfront first line therapy for patients with aggressive non-Hodgkin s lymphoma does not contribute to a better outcome, most certainly not if it concerns patients with a favorable risk profile. " 02/01/1998 - "The aim of the study was to retrospectively evaluate the outcome of patients with aggressive non-Hodgkin's lymphoma (NHL), undergoing autologous stem cell transplantation (ASCT) in first complete (CR) or partial (PR) remission, according to the age-adjusted International Prognostic Index (IPI). " 06/01/2005 - "Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40." 03/01/2005 - "Thus, large randomized trials are required to fully define the role of autologous stem cell transplantation in first-line treatment for high-risk non-Hodgkin lymphoma. " 01/01/2008 - "Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma." Order ALL the reference details at left...
5.	Radioimmunotherapy 02/01/2006 - "Radioimmunotherapy has proven clinically effective in patients with non-Hodgkin's lymphoma. " 05/01/2004 - "Radioimmunotherapy produces overall response rates of approximately 80% in patients with low-grade lymphomas, and 25% to 30% of patients achieve a complete remission. " 06/01/2004 - "Radioimmunotherapy (RIT) using (131)I-tositumomab has been used successfully to treat relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). " 11/01/2008 - "Radioimmunotherapy is an effective treatment for non-Hodgkin's lymphoma (NHL). " 07/01/2008 - "Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody." Order ALL the reference details at left...